Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

Editorial: Immune checkpoint inhibitors in renal cell carcinoma von Tykodi, Scott S, Pichler, Renate

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer von Brahmer, Julie R, Tykodi, Scott S, Chow, Laura Q.M, Hwu, Wen-Jen, Topalian, Suzanne L, Hwu, Patrick, Drake, Charles G, Camacho, Luis H, Kauh, John, Odunsi, Kunle, Pitot, Henry C, Hamid, Omid, Bhatia, Shailender, Martins, Renato, Eaton, Keith, Chen, Shuming, Salay, Theresa M, Alaparthy, Suresh, Grosso, Joseph F, Korman, Alan J, Parker, Susan M, Agrawal, Shruti, Goldberg, Stacie M, Pardoll, Drew M, Gupta, Ashok, Wigginton, Jon M

Volltext

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma von Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander, Cho, Daniel C., Guan, Shanhong, Puente, Erika, Tuan Nguyen, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.

Volltext

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... von Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M

Volltext

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system von Miller, Chris P, Fung, Megan, Jaeger-Ruckstuhl, Carla A, Xu, Yuexin, Warren, Edus H, Akilesh, Shreeram, Tykodi, Scott S

Volltext

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma von Rini, Brian I, Signoretti, Sabina, Choueiri, Toni K, McDermott, David F, Motzer, Robert J, George, Saby, Powles, Thomas, Donskov, Frede, Tykodi, Scott S, Pal, Sumanta K, Gupta, Saurabh, Lee, Chung-Wei, Jiang, Ruiyun, Tannir, Nizar M

Volltext

Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor von Tretiakova, Maria S., Kehr, Elizabeth L., Gore, John L., Tykodi, Scott S.

Volltext

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors von Xu, Yuexin, Miller, Chris P, Tykodi, Scott S, Akilesh, Shreeram, Warren, Edus H

Volltext

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma von Yang, Yuanquan, Psutka, Sarah P., Parikh, Anish B., Li, Mingjia, Collier, Katharine, Miah, Abdul, Mori, Sherry V., Hinkley, Megan, Tykodi, Scott S., Hall, Evan, Thompson, John A., Yin, Ming

Volltext

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era von Macleod, Liam C, Tykodi, Scott S, Holt, Sarah K, Wright, Jonathan L, Lin, Daniel W, Tretiakova, Maria S, True, Lawrence D, Gore, John L

Volltext

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded cl... von Xu, Yuexin, Morales, Alicia J., Towlerton, Andrea M. H., Akilesh, Shreeram, Miller, Chris P., Tykodi, Scott S., Warren, Edus H.

Volltext

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p... von George, Daniel J, Spigel, David R, Gordan, Lucio N, Kochuparambil, Samith T, Molina, Ana M, Yorio, Jeff, Rezazadeh Kalebasty, Arash, McKean, Heidi, Tchekmedyian, Nishan, Tykodi, Scott S, Zhang, Joshua, Askelson, Margarita, Johansen, Jennifer L, Hutson, Thomas E

Volltext

Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order von Warren, Edus H, Vigneron, Nathalie J, Gavin, Marc A, Coulie, Pierre G, Stroobant, Vincent, Dalet, Alexandre, Tykodi, Scott S, Xuereb, Suzanne M, Mito, Jeffrey K, Riddell, Stanley R, Eynde, Benoît J. Van den

Volltext

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab von Veatch, Joshua R, Singhi, Naina, Jesernig, Brenda, Paulson, Kelly G, Zalevsky, Jonathan, Iacucci, Ernesto, Tykodi, Scott S, Riddell, Stanley R

Volltext

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma von McDermott, David F., Lee, Jae-Lyun, Bjarnason, Georg A., Larkin, James M. G., Gafanov, Rustem A., Kochenderfer, Mark D., Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S., Alonso-Gordoa, Teresa, Cho, Daniel C., Geertsen, Poul F., Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F., Schloss, Charles, Atkins, Michael B.

Volltext

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 von Rini, B.I., Tannir, N.M., Escudier, B., McDermott, D.F., Grimm, M.-O., Porta, C., Powles, T., Kollmannsberger, C.K., Gurney, H.P., Tykodi, S.S., Harrison, M., Heng, D.Y.C., Grünwald, V., Choueiri, T.K., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J., George, S.

Volltext

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial... von Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

Volltext

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study von Choueiri, Toni K, McDermott, David F, Merchan, Jaime, Bauer, Todd M, Figlin, Robert, Heath, Elisabeth I, Michaelson, M Dror, Arrowsmith, Edward, D'Souza, Anishka, Zhao, Song, Roy, Ananya, Perini, Rodolfo, Vickery, Donna, Tykodi, Scott S

Volltext